



Supplemental Figure 1. (a) Expression of the *Ccl6* and *Ccl22* were decreased ($p < 0.05$, ANOVA with Tukey's HSD) in neurofibromas from FLLL32-treated mice relative to vehicle. *Ccl6* was also reduced in neurofibromas from *Dhh-Cre; Nf1^{fl/fl}; Stat3^{fl/fl}* mice relative to vehicle-treated *Dhh-Cre; Nf1^{fl/fl}* animals. **(b)** Vehicle samples were subgrouped by their rate-of-growth (Fast-growth: $>35\text{mm}^3$ over 60 days, Slow-growth: $<5\text{mm}^3$ over 60 days). FLLL32 treated samples were segregated by response to therapy (responders: tumor shrinkage during 60 day FLLL32 treatment, non-responders: continued growth during the treatment period). Neither *Ccl6* nor *Ccl22* were differentially expressed between fast-growing neurofibromas relative to slow-growing, or between responders and non-responders.